Cooley Advises Versartis on its $145 Million IPO

Palo Alto, Calif. – March 31, 2014 – Cooley LLP announced today that it advised Versartis, Inc. on its $144.9 million initial public offering. Versartis, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of endocrine disorders, now trades on the NASDAQ Global Stock Market under the symbol "VSAR."

The Cooley corporate and securities team advising Versartis included partner and head of the life sciences practice Barbara Kosacz, partners Kenn Guernsey and Mike Tenta, and associates Siana Lowrey, Amanda Busch and Alexis Weiss. Critical support for the offering was provided by partner Renee Deming and associate Sarah Dale (compensation & benefits); partner Natasha Leskovsek (regulatory); partner Michael Tuscan and associate Fraser Brown (patent counseling & prosecution); and associate Bin Wang (life sciences).

Year-to-date in 2014, Cooley has advised on 38 completed public offerings, including 17 completed IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
Kenneth Guernsey Partner, San Francisco
Barbara Kosacz Partner, Palo Alto
Michael Tenta Partner, Palo Alto
Michael Tuscan Partner in Charge - Washington, DC
Bin Wang Associate, Beijing
Natasha Leskovsek Partner, Washington, DC
Renee Deming Retired Partner, Palo Alto
Amanda Busch Associate, San Francisco
Siana Lowrey Partner, San Francisco
Fraser Brown Partner, Washington, DC